We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Diagnostic Test for Hepatitis C Developed with Scrapbooking Tool

By LabMedica International staff writers
Posted on 17 Jun 2014
Scientists have used a novel approach to develop a paper-based multiplex diagnostic immunoassay that could help curb the hepatitis C pandemic.

For patients already diagnosed with Hepatitis C virus (HCV), the US Food and Drug Administration (FDA) approved two new treatments in late 2013, and others are on the way. More...
Scientists Xuan Mu, Zhi Zheng, and colleagues, of the Chinese Academy of Medical Sciences (Beijing, China), are solving another critical problem—identifying the millions more who unknowingly have the virus and pass it on. They point out that although HCV infects an estimated 150 million people worldwide, current diagnostic testing involves initial screening then a costly second test for confirmation. The extra office visits, money, and time required for definitive diagnosis means that many people are missed as they cannot or do not follow through.

To make diagnosis much more accessible, the researchers applied the recent development of inexpensive paper-based medical technologies to immunoassay detection of human IgG anti-HCV. In a new report they present a novel approach: taking example from the popular scrapbooking pastime, they used a flower-shaped metal paper-puncher on nitrocellulose paper subtrate. This solved the problem of patterning the highly flammable nitrocellulose—without using heat. The flower shape itself provides multiple testing zones, enabling development of a multiplex test. The immunoassays can be conducted such that both HCV tests can be conducted simultaneously on one patient sample on a single flower-shaped paper – at lower cost and in minutes instead of hours.

The work highlights the potential of microfluidic paper-based immunoassays in tackling the diagnostic challenge for the HCV pandemic as well as other diseases. Xuan M., et al. described the new test in the American Chemical Society journal Analytical Chemistry, May 5, 2014, online, ahead of print.

Related Links:

Chinese Academy of Medical Sciences



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.